MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development

doi:10.1111/hepr.12737

	MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development
	Wu, Liangcai 1,4; Bai, Xue 1; Xie, Yuan 1; Yang, Zhen 5; Yang, Xiaobo 1; Lin, Jianzhen 1; Zhu, Chengpei 1; Wang, Anqiang 1; Zhang, Haohai 1; Miao, Ruoyu 1,6,7,8; Wu, Yan 6,7,8; Robson, Simon C.6,7,8; Zhao, Yi 1,4; Sang, Xinting 1; Zhao, Haitao 1,2,3
	2017
发表期刊	HEPATOLOGY RESEARCH
ISSN	1386-6346
卷号	47 期号:1 页码:80-94
摘要	Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide, which can be explained at least in part by its propensity towards metastasis and the limited efficacy of adjuvant therapy. MetastamiRs are miRNAs that promote or suppress migration and metastasis of cancer cells, and their functional status is significantly correlated with HCC prognosis. Unlike targeted therapy, metastamiRs have the potential to target multiple genes and signaling pathways and dramatically suppress cancer metastasis. In this review, we discuss the regulatory role of metastamiRs in the HCC invasion-metastasis cascade. Moreover, Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis has shown that many extensively studied metastamiRs target several critical signaling pathways and these have remarkable therapeutic potential in HCC. The information reviewed here may assist in further anti-HCC miRNA drug screening and development.
关键词	hepatocellular carcinoma metastasis microRNA
DOI	10.1111/hepr.12737
收录类别	SCI
语种	英语
资助项目	International Science and Technology Cooperation Projects[2015DFA30650] ; International Science and Technology Cooperation Projects[2010DFB33720] ; Capital Special Research Project for Health Development[2014-2-4012] ; Capital Research Project for the Characteristics Clinical Application[Z151100004015170] ; Program for New Century Excellent Talents in University[NCET-11-0288]
WOS研究方向	Gastroenterology & Hepatology
WOS类目	Gastroenterology & Hepatology
WOS记录号	WOS:000392432200008
出版者	WILEY-BLACKWELL
引用统计	被引频次：4[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://119.78.100.204/handle/2XEOYT63/7621
专题	中国科学院计算技术研究所期刊论文_英文
通讯作者	Zhao, Haitao
作者单位	1.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Liver Surg, Beijing, Peoples R China 2.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Ctr Translat Med, 1 Shuaifuyuan, Beijing 100730, Peoples R China 3.Peking Union Med Coll, 1 Shuaifuyuan, Beijing 100730, Peoples R China 4.Chinese Acad Sci, Inst Comp Technol, Key Lab Intelligent Informat Proc, Beijing, Peoples R China 5.CAS MPG Partner Inst Computat Biol, Key Lab Computat Biol, Shanghai, Peoples R China 6.Harvard Med Sch, Beth Israel Deaconess Med Ctr, Liver Ctr, Brookline, MA USA 7.Harvard Med Sch, Beth Israel Deaconess Med Ctr, Transplant Inst, Dept Med, Brookline, MA USA 8.Harvard Med Sch, Beth Israel Deaconess Med Ctr, Transplant Inst, Dept Surg, Brookline, MA USA
推荐引用方式 GB/T 7714	Wu, Liangcai,Bai, Xue,Xie, Yuan,et al. MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development[J]. HEPATOLOGY RESEARCH,2017,47(1):80-94.
APA	Wu, Liangcai.,Bai, Xue.,Xie, Yuan.,Yang, Zhen.,Yang, Xiaobo.,...&Zhao, Haitao.(2017).MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development.HEPATOLOGY RESEARCH,47(1),80-94.
MLA	Wu, Liangcai,et al."MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development".HEPATOLOGY RESEARCH 47.1(2017):80-94.